Disease indications



Infectious Diseases

Influenza and Covid-19

Influenza (Flu) and Covid-19 are contagious respiratory illnesses caused by influenza and SARS-CoV-2 viruses respectively and infect the respiratory tract. Usual symptoms for both include fever, headache, muscle ache, coughing and sneezing. Covid-19 symptoms may also specifically include lack of smell and/or lack of taste. The severity of symptoms for both illnesses depends on a person’s level of immunity. Ethris aims to leverage its proprietary SNIM® RNA technology to develop a first-in-class, anti-viral treatment for influenza and Covid-19 by activating the body’s innate immune system specifically in locations where the virus enters the body. By targeting the mRNA to the lung, we can facilitate the antiviral defense directly in patients’ lungs and can significantly impact the viral infection process. Our program is a differentiated approach that can also treat other seasonal and potentially newly emerging respiratory viruses.



mRNA-based Protein Replacement Therapies


PCD – Primary Ciliary Dyskinesia

Primary Ciliary Dyskinesia (PCD) is a rare disease that arises from structural defects or the absence of the cilia lining our respiratory tract. With the cilia unable to function, mucus loaded with trapped microbes, dust, and other debris cannot be cleared from the airways efficiently and can often lead to permanent lung damage. With our SNIM®RNA technology we can deliver a corrected mRNA that is designed to produce ciliary proteins in the respiratory tract thereby reconstituting cilia function.



PAP – Pulmonary Alveolar Proteinosis

Pulmonary alveolar proteinosis (PAP) is a rare autoimmune disease that results in difficulties in breathing due to reduced gas exchange in the lung. The underlying cause of disease in~90%   of patients is the formation of autoantibodies against GM-CSF, which results in dysfunction of local macrophages and subsequently causes the lung’s tiny air sacs, called alveoli, to fill up with an oily substance called surfactant. There is currently no approved curative pharmacotherapy available. Inhalation of recombinant GM-CSF (rGM-CSF) has limited clinical efficacy due to high levels of endogenous anti-GM-CSF antibodies and the potential for further induction of anti-drug-antibody following treatment with recombinant protein. Our SNIM® RNA-carrier complex can be delivered directly to the lung to restore local macrophage function.

Delivery of corrected mRNA to maturing epithelial cells in the airways via our SNIM® RNA technology, leading to growth of normal functional cilia.

View our full pipeline here.